PTC Therapeutics, Inc. announced the pricing of a public offering of 2,475,248 shares of its common stock at a public offering price of $40.40 per share, before underwriting discounts and commissions.
SOUTH PLAINFIELD, N.J., Sept. 18, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (Nasdaq: PTCT) announced today the pricing of a public offering of 2,475,248 shares of its common stock at a public offering price of $40.40 per share, before underwriting discounts and commissions. In addition, PTC has granted the underwriter an option for a period of 30 days to purchase up to an additional 371,287 shares of common stock at the public offering price, less the underwriting discount.
Credit Suisse is acting as the sole bookrunning manager for the public offering of common stock.
PTC expects to close the offering on or about September 20, 2019, subject to satisfaction of customary closing conditions. The offering of the common stock by PTC is not contingent upon the consummation of the previously announced concurrent private offering of the convertible senior notes (the “Notes”), and the concurrent private offering of the Notes is not contingent upon the consummation of the offering of common stock by PTC.
An automatically effective shelf registration statement on Form S-3 (File No. 333-220151) relating to the shares of common stock offered in the public offering has been filed with the Securities and Exchange Commission (the “SEC”) and is available on the SEC’s website at www.sec.gov. A final prospectus supplement relating to and describing the terms of the offering also will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Before investing in the offering, interested parties should read the prospectus supplement and the accompanying prospectus for the offering and the other documents PTC has filed with the SEC that are incorporated by reference in the prospectus supplement and the accompanying prospectus, which provide more complete information about PTC and the offering. Copies of the prospectus supplement and the accompanying prospectus relating to the offering may be obtained from: Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, Eleven Madison Avenue, 3rd floor, New York, NY 10010, or by telephone: (800) 221-1037, or by emailing usa.prospectus@credit-suisse.com.
This press release does not constitute an offer to sell, or a solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.
About PTC Therapeutics
PTC is a science-led, global biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders. PTC’s ability to globally commercialize products is the foundation that drives investment in a robust pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need.
For More Information:
Investors:
Emily Hill
+1 (908) 912-9327
ehill@ptcbio.com
Media:
Jane Baj
+1 (908) 912-9167
jbaj@ptcbio.com
View original content:http://www.prnewswire.com/news-releases/ptc-therapeutics-announces-pricing-of-public-offering-of-common-stock-300920713.html
SOURCE PTC Therapeutics, Inc.
Company Codes: NASDAQ-NMS:PTCT
